Literature DB >> 35789435

Contribution of specific ceramides to obesity-associated metabolic diseases.

Philipp Hammerschmidt1,2,3, Jens C Brüning4,5,6,7.   

Abstract

Ceramides are a heterogeneous group of bioactive membrane sphingolipids that play specialized regulatory roles in cellular metabolism depending on their characteristic fatty acyl chain lengths and subcellular distribution. As obesity progresses, certain ceramide molecular species accumulate in metabolic tissues and cause cell-type-specific lipotoxic reactions that disrupt metabolic homeostasis and lead to the development of cardiometabolic diseases. Several mechanisms for ceramide action have been inferred from studies in vitro, but only recently have we begun to better understand the acyl chain length specificity of ceramide-mediated signaling in the context of physiology and disease in vivo. New discoveries show that specific ceramides affect various metabolic pathways and that global or tissue-specific reduction in selected ceramide pools in obese rodents is sufficient to improve metabolic health. Here, we review the tissue-specific regulation and functions of ceramides in obesity, thus highlighting the emerging concept of selectively inhibiting production or action of ceramides with specific acyl chain lengths as novel therapeutic strategies to ameliorate obesity-associated diseases.
© 2022. The Author(s).

Entities:  

Keywords:  Atherosclerosis; Ceramide acyl chain length; Diabetes; High-fat diet; Insulin resistance; Lipid signaling; Lipotoxicity; Metabolic disease treatment; Obesity; Sphingolipids

Mesh:

Substances:

Year:  2022        PMID: 35789435      PMCID: PMC9252958          DOI: 10.1007/s00018-022-04401-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.207


  357 in total

1.  1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo.

Authors:  J Turinsky; D M O'Sullivan; B P Bayly
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

Review 2.  Many ceramides.

Authors:  Yusuf A Hannun; Lina M Obeid
Journal:  J Biol Chem       Date:  2011-06-21       Impact factor: 5.157

3.  Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.

Authors:  William L Holland; Joseph T Brozinick; Li-Ping Wang; Eric D Hawkins; Katherine M Sargent; Yanqi Liu; Krishna Narra; Kyle L Hoehn; Trina A Knotts; Angela Siesky; Don H Nelson; Sotirios K Karathanasis; Greg K Fontenot; Morris J Birnbaum; Scott A Summers
Journal:  Cell Metab       Date:  2007-03       Impact factor: 27.287

Review 4.  Childhood obesity: public-health crisis, common sense cure.

Authors:  Cara B Ebbeling; Dorota B Pawlak; David S Ludwig
Journal:  Lancet       Date:  2002-08-10       Impact factor: 79.321

Review 5.  Lipid homeostasis, lipotoxicity and the metabolic syndrome.

Authors:  Roger H Unger; Gregory O Clark; Philipp E Scherer; Lelio Orci
Journal:  Biochim Biophys Acta       Date:  2009-11-27

Review 6.  Adipose tissue dysfunction contributes to obesity related metabolic diseases.

Authors:  Matthias Blüher
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-03-06       Impact factor: 4.690

Review 7.  Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms.

Authors:  Jose Antonio Chavez; Scott A Summers
Journal:  Biochim Biophys Acta       Date:  2009-09-29

8.  Ceramide content is increased in skeletal muscle from obese insulin-resistant humans.

Authors:  John M Adams; Thongchai Pratipanawatr; Rachele Berria; Elaine Wang; Ralph A DeFronzo; M Cameron Sullards; Lawrence J Mandarino
Journal:  Diabetes       Date:  2004-01       Impact factor: 9.461

Review 9.  Obesity: global epidemiology and pathogenesis.

Authors:  Matthias Blüher
Journal:  Nat Rev Endocrinol       Date:  2019-05       Impact factor: 43.330

10.  Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance.

Authors:  Jacob M Haus; Sangeeta R Kashyap; Takhar Kasumov; Renliang Zhang; Karen R Kelly; Ralph A Defronzo; John P Kirwan
Journal:  Diabetes       Date:  2008-11-13       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.